Focus on infection prevention technology and strategic partnerships drives growth in high-need therapeutic areas. Q1 2025 saw revenue and EBITDA gains, with ambitious targets set for 2030.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.